Sex-based analysis of health outcomes and health service utilization associated with diabetes and cardiovascular conditions and examination of PharmaCheck medication review service in New Brunswick
Category(s):
Health
Status: Active
Principal: Chris Folkins
Project Number: P0113
Year Approved: 2023
Project Description
This project, undertaken in collaboration with Shoppers Drug Mart Inc., will use administrative data accessed via NB-IRDT to conduct research related to the provision of pharmacy services in New Brunswick. The primary research objectives of the project are:
- Examine health outcomes and health service utilization associated with diabetes and cardiovascular conditions among New Brunswick residents overall, by geography, and by socioeconomic and demographic characteristics, separating each dimension by sex. Findings from this study will be useful in identifying potential target geographic areas and socioeconomic/demographic groups of interest for pharmacy-based interventions.
- Examine PharmaCheck medication review service utilization and associated outcomes in NB. PharmaCheck is a medication review service performed at the pharmacy by a pharmacist. It entails a detailed review of a patient’s medication profile, with the purpose of identifying drug therapy problems and making improvements to medication therapy management. NB residents are eligible to receive the provincially funded PharmaCheck service once per year if they are a New Brunswick Prescription Drug Program Beneficiary, covered under the plan for seniors (age 65+) or Social Development clients, and taking 3 or more chronic prescription medications.
Our analysis will describe the incidence and distribution (geographic, demographic) of PharmaCheck medication review services by pharmacists in New Brunswick, and project potential growth of PharmaCheck service volume anticipated with expansion of eligibility criteria. We will also examine health/health service utilization outcomes associated with PharmaCheck services, estimate reduction in adverse outcomes and potential cost savings associated with current PharmaCheck service volumes, and estimate additional reduction in adverse outcomes and cost savings anticipated with expansion of PharmaCheck eligibility criteria.
